PharmacoEconomics

Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?
pp. 211-213(3)
Author: Hughes, Dyfrig

Aromatase Inhibitors in Breast Cancer: A Review of Cost Considerations and Cost Effectiveness
pp. 215-232(18)
Author: Karnon, Jonathan

Trends in Outpatient Prescription Drug Use and Related Costs in the US: 1998-2003
pp. 233-236(4)
Authors: Wysowski, Diane K.; Governale, Laura A.; Swann, Joslyn

Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: The UK Perspective
pp. 237-250(14)
Authors: Karnon, Jonathan; Delea, Thomas; Johnston, Stephen R.D.; Smith, Robert; Brandman, Jane; Sung, Jennifer; Goss, Paul E.

Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications
pp. 251-264(14)
Authors: Goldberg, Lawrence D.; Walt, John

Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer's Disease and Other Dementias
pp. 265-280(16)
Authors: Hill, Jerrold; Fillit, Howard; Thomas, Simu K.; Chang, Sobin

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women
pp. 281-292(12)
Authors: Milne, Richard J.; Heaton-Brown, Kathy H.; Hansen, Paul; Thomas, David; Harvey, Vernon; Cubitt, Alison

Eliciting Social Preference Weights for Functional Assessment of Cancer Therapy-Lung Health States
pp. 293-294(2)
Authors: Pickard, A. Simon; Dobrez, Deborah; Cella, David

The Authors' Reply
pp. 294-296(3)
Authors: Kind, Paul; Macran, Sue

Bimatoprost: A Pharmacoeconomic Review of its Use in Open-Angle Glaucoma and Ocular Hypertension
pp. 297-314(18)
Authors: Plosker, Greg L.; Keam, Susan J.